P
ProLynx
Extending medicine impact with ultra-long-acting therapies
About ProLynx
ProLynx is an innovative biotechnology company focused on developing ultra-long-acting medicines to transform the treatment of obesity and related metabolic diseases. At the heart of ProLynx’s work is a proprietary half-life extension technology that enables therapeutic candidates to be dosed once monthly or once quarterly, offering a promising alternative to current therapies that require more frequent administration. This approach aims to improve treatment consistency, tolerability and patient outcomes by smoothing pharmacokinetic profiles and enhancing long-term adherence.
Read full description
Headquartered in the San Francisco Bay Area, ProLynx advances a next-generation portfolio of extended-duration therapeutic programs while actively collaborating with top biotech investors and scientific partners. Backed by leading venture firms including 5AM Ventures, OrbiMed and Monograph Capital, the company recently secured a significant Series A financing to accelerate its pipeline and leadership team. With deep scientific roots and an emphasis on addressing unmet medical needs through novel drug delivery mechanisms, ProLynx is positioned to redefine the standards of care in metabolic disease therapeutics.
At a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Emeryville, United States
- Employees
- 34
- Open positions
- 4
- Dealroom signal
- 59.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Weight Management, Metabolism, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2025 | $70M | $280M | Monograph Capital · 5AM Ventures · OrbiMed | ↗ |
| GRANTOther financing | Jul 2020 | $230K | — | National Institutes of Health | — |
Growth signals
Latest recorded traffic for ProLynx is 1.7K monthly website visits, up 2733.3% over the last three months. ProLynx's team grew 36% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
US National Science Foundation
Series A3 investors entered at this stage
Monograph Capital
5AM Ventures
OrbiMed
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ProLynx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ProLynx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.